Toxicology and clinical protocol development of DUO-207: An ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel for the treatment of metastatic pancreatic cancer. This is an ASCO Meeting ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Disparities in outcomes of pancreatic cancer hospitalizations: A ten-year trend study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

Chemoradiation is considered a reasonable treatment option for patients with locally advanced, unresectable pancreatic cancer. The chemotherapy agents 5-fluorouracil, gemcitabine, capecitabine and ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.

The San Francisco biotech confirmed that neither the PanCAN Precision Promise study in metastatic pancreatic cancer nor the LAPIS trial in patients with locally advanced, unresectable pancreatic ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Feb. 18, 2025 — Pancreatic cancer (PC) is the worst prognosis cancer globally, with just 13% of patients who are diagnosed with PC surviving for 5 years or more after initial diagnosis.

Historically, high-dose radiation has been considered beneficial for improving survival rates in patients with unresectable pancreatic cancer. Yet, the application has often been limited due to ...

which is designed for treating locally advanced unresectable pancreatic cancer. The device offers a targeted treatment approach by delivering Phosphorous-32 directly into pancreatic tumors ...